Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
Event:
ESC CONGRESS 2019
Topic:
Cardiovascular Disease in Special Populations
Session type:
Satellite Symposium
Sponsored by Novo Nordisk A/S
Date:
1 September 2019
Time:
13:00
-
14:00
Session
5 presentations in this session
Examining the link: type 2 diabetes and cardiovascular disease
Speaker:
Professor L. Ryden (Stockholm, SE)
Gazing into the future opportunities of glucagon-like peptide-1 receptor agonists in cardiovascular disease
Speaker:
Professor S. Verma (Toronto, CA)
“Belling the Cat” - Practical guide for cardiologists on Incorporating GLP-1RAs into comprehensive cardiovascular risk reduction
Speaker:
Doctor M. Kosiborod (Kansas City, US)
Connecting with the speakers - Questions and answers
Speaker:
Professor L. Ryden (Stockholm, SE)
Speaker:
Professor S. Verma (Toronto, CA)
Speaker:
Doctor M. Kosiborod (Kansas City, US)
7 speakers from this session
Professor Lars
Ryden
Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
31
presentations
0
follower
Professor Lars
Ryden
Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
31
presentations
0
follower
Professor Subodh
Verma
St. Michael's Hospital, Toronto (Canada)
16
presentations
0
follower
Doctor Mikhail
Kosiborod
St. Luke's Mid America Heart Institute, Kansas City (United States of America)
23
presentations
0
follower
Professor Lars
Ryden
Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
31
presentations
0
follower
Professor Subodh
Verma
St. Michael's Hospital, Toronto (Canada)
16
presentations
0
follower
Doctor Mikhail
Kosiborod
St. Luke's Mid America Heart Institute, Kansas City (United States of America)
23
presentations
0
follower
This platform is supported by
